期刊文献+

胰腺神经内分泌肿瘤CT征象与SSTR2、VEGFR2及MGMT表达的关系 被引量:2

Relationship of CT signs and Expression of SSTR2,VEGFR2 and MGMT in Pancreatic Neuroendocrine Neoplasms
下载PDF
导出
摘要 【目的】探讨胰腺神经内分泌肿瘤(pNENs)的CT征象与生长抑素2型受体(SSTR2)、血管内皮生长因子2型受体(VEGFR2)及O^(6)-甲基鸟嘌呤-DNA甲基转移酶(O^(6)-methylguanine-DNA-methyltransferse,MGMT)表达的关系。【方法】收集2010年1月至2020年11月本机构经术后病理证实为pNENs 86例,所有患者术前均行增强CT检查,术后行SSTR2、VEGFR2、MGMT免疫组化检查。回顾性分析pNENs的CT特征与SSTR2、VEGFR2及MGMT表达情况的相关性,采用独立样本t检验或非参数检验及ROC曲线进行分析。【结果】SSTR2(+)组及SSTR2(-)组在性别、边界的差异有统计学意义(P<0.05),VEGFR2(+)组及VEGFR2(-)组在性别、最大径线≥20 cm、边界、强化率(动脉期、静脉期)及CT值比率(静脉期)的差异有统计学意义(P<0.05),MGMT(+)组及MGMT(-)组在最大径线≥20 cm、最大径、边界、强化率(动脉期)及CT值比率(平扫、动脉期、静脉期)的差异有统计学意义(P<0.05)。CT征象评估SSTR2、VEGFR2及MGMT阳性表达的AUC分别为0.847、0.761和0.749,灵敏度分别为87.18%,76.67%和90.48%,特异度分别为87.50%,73.91%和57.14%。【结论】CT征象联合临床特征可以反映pNENs中SSTR2、VEG⁃FR2及MGMT的表达。 【Objective】To investigate the relationship between CT signs and expression of somatostatin receptor type 2(SSTR2),vascular endothelial growth factor receptor type 2(VEGFR2)and O^(6)-methylguanine-DNA-methyltransferse(MGMT)in pancreatic neuroendocrine neoplasms(pNENs).【Methods】The data of 86 pNENs patients confirmed by histopathology were retrospectively analyzed,including CT imaging and expression of SSTR2,VEGFR2 and MGMT.Their correlations were identified by independent-samples t test,non-parametric test and receiver operating characteristic(ROC)curves.【Results】Gender and tumor boundary were significantly different between SSTR2-positive and SSTR2-negative pNENs patients(P<0.05).Gender,maximum diameter≥20 cm,boundary,enhancement ratio(arterial and venous phase)and CT value ratio(venous phase)were significantly different between VEGFR2-positive and VEGFR2-negative pNENs patients(P<0.05).Maximum diameter,maximum diameter≥20 cm,enhancement ratio(arterial phase)and CT value ratio(plain,arterial and venous phase)were significantly different between MGMT-positive and MGMT-negative pNENs patients(P<0.05).The AUCs of CT signs assessing positive expression of SSTR2,VEGFR2 and MGMT were 0.847,0.761 and 0.749 respectively,with sensitivity of 87.18%,76.67%and 90.48%respectively,specificity of 87.50%,73.91%and 57.14%respectively.【Conclusions】CT features combined with clinical manifestations can reflect expression of SSTR2,VEGFR2 and MGMT in pNENs.
作者 李璐杰 宋晨宇 周小琦 罗宴吉 冯仕庭 彭振鹏 LI Lu-jie;SONG Chen-yu;ZHOU Xiao-qi;LUO Yan-ji;FENG Shi-ting;PENG Zhen-peng(Department of Diagnostic Radiology,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2021年第6期892-899,共8页 Journal of Sun Yat-Sen University:Medical Sciences
基金 国家自然科学基金(81571750) 中华国际医学交流基金会2020SKY影像科研基金(Z-2014-07-2003-07)。
关键词 胰腺神经内分泌肿瘤 计算机断层扫描 生长抑素2型受体 血管内皮生长因子2型受体 O^(6)-甲基鸟嘌呤-DNA甲基转移酶 pancreatic neuroendocrine neoplasms computer tomography somatostatin receptor type 2 vascular endothelial growth factor receptor type 2 O6-methylguanine-DNA-methyltransferse
  • 相关文献

参考文献2

二级参考文献22

  • 1何天霖,胡先贵,张怡杰,刘瑞,邵成浩.胰腺神经内分泌肿瘤的外科诊治[J].中华普通外科杂志,2007,22(7):494-496. 被引量:3
  • 2KLOPPEL G,PERREN A,HEITZ P U.The gastroenteropancreatic neuroendocrine cell system and its tumors:the WHO classification[J].Ann N Y Acad Sci,2004,1014:13-27.
  • 3FRAENKEL M,KIM M K,FAGGIANO A,et al.Epidemiology of gastroenteropancreatic neuroendocrine tumours[J].Best Pract Res Clin Gastroenterol,2012,26(6):691-703.
  • 4MUNIRAJ T,VIGNESH S,SHETTY S,et al.Pancreatic neuroendocrine tumors[J].Dis Mon,2013,59(1):5-19.
  • 5FISCHER L,KLEEFF J,ESPOSITO I,et al.Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas[J].Br J Surg,2008,95(5):627-635.
  • 6LEGMANN P,VIGNAUX O,DOUSSET B,et al.Pancreatic tumors:comparison of dual-phase helical CT and endoscopic sonography[J].AJR Am J Roentgenol,1998,170(5):1315-1322.
  • 7DROMAIN C,DE BAERE T,LUMBROSO J,et al.Detection of liver metastases from endocrine tumors:a prospective comparison of somatostatin receptor scintigraphy,computed tomography,and magnetic resonance imaging[J].J Clin Oncol,2005,23(1):70-78.
  • 8ISHIKAWA T,ITOH A,KAWASHIMA H,et al.Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors[J].Gastrointest Endosc,2010,71(6):951-959.
  • 9ARVOLD N D,WILLETT C G,FERNANDEZ DEL C C,et al.Pancreatic neuroendocrine tumors with involved surgical margins:prognostic factors and the role of adjuvant radiotherapy[J].Int J Radiat Oncol Biol Phys,2012,83(3):e337-e343.
  • 10STROSBERG J R,CHEEMA A,WEBER J,et al.Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors[J].J Clin Oncol,2011,29(22):3044-3049.

共引文献38

同被引文献18

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部